A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Clinical trial NCT06346067 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06346067
- Sponsor
- Erasca, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-29
- Primary completion
- 2028-04-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.